Vor Bio starts global phase 3 trial for Sjogren's disease treatment

March 30, 2026 8:01 AM

Vor Bio (NASDAQ: VOR) announced it has dosed the first patient in UPSTREAM SjD, a global phase 3 trial testing ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found